login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ACRIVON THERAPEUTICS INC (ACRV) Stock News
NASDAQ:ACRV - Nasdaq -
US0048901096
-
Common Stock
- Currency: USD
1.25
-0.02 (-1.57%)
Summary
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ACRV Latest News, Press Relases and Analysis
All
Press Releases
3 months ago - By: Yahoo Finance
- Mentions:
BNS
FLO
BMO
RY
...
Scotiabank price target raised to C$71 from C$70 at BofA
3 months ago - By: Yahoo Finance
Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch
3 months ago - By: Yahoo Finance
- Mentions:
CL
WMT
NVDA
AEP
...
Jim Cramer Says Colgate-Palmolive “Could Go Lower”
3 months ago - By: Zacks Investment Research
- Mentions:
HUM
COR
ADUS
Can Humana Beat Q1 Earnings Estimates on Growing Premiums?
4 months ago - By: Zacks Investment Research
- Mentions:
COR
HCA
TARS
HCA Healthcare to Report Q1 Earnings: Key Estimates to Note
4 months ago - By: Zacks Investment Research
- Mentions:
THC
COR
CNC
Can Centene Beat Q1 Earnings Estimates on Growing Premiums?
3 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
3 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
3 months ago - By: Benzinga
- Mentions:
PBM
CNMD
FOLD
BCDA
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
4 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025
4 months ago - By: Zacks Investment Research
- Mentions:
UHS
COR
TARS
Universal Health to Report Q1 Earnings: Can it Surprise Wall Street?
4 months ago - By: Zacks Investment Research
- Mentions:
MOH
COR
TARS
Molina Healthcare to Report Q1 Earnings: Key Estimates to Watch
4 months ago - By: Benzinga
- Mentions:
ICAD
SYRA
BMRA
SXTC
...
12 Health Care Stocks Moving In Wednesday's Intraday Session
4 months ago - By: Zacks Investment Research
Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV)
4 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
4 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer
4 months ago - By: Zacks Investment Research
Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know
4 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
4 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results
5 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
5 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates
6 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
6 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer
9 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
9 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
10 months ago - By: Acrivon Therapeutics, Inc
Acrivon Therapeutics to Present Data Demonstrating Deployment of its AP3 Platform for Streamlined Drug Discovery and Clinical Development at Two Scientific Conferences - Human Proteome Organization World Congress and EORTC-NCI-AACR Symposium
Please enable JavaScript to continue using this application.